Aura Biosciences, Inc. – NASDAQ:AURA

Add to watchlist

$6.4

-1.92

-23.17%

Market open

Closed in 40 minutes

-2.69%

month

-2.69%

quarter

-8.36%

year

Market Cap	404.85M
Enterprise value	163.62M

P/E	-4.88
EV/Sales	N/A
EV/EBITDA	-1.95
Price/Sales	N/A
Price/Book	1.35
PEG ratio	-0.06
EPS	-1.85

Revenue	N/A
EBITDA	-84.95M
Income	-78.64M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Aura Biosciences Stock Forecast

M Q Y

Last Year

$23

Potential upside: 259.37%

Analysts Price target
Financials & Ratios estimates

Aura Biosciences, Inc. (NASDAQ:AURA): Profit margin
Jun 2023	0	-18.29M
Sep 2023	0	-18.51M
Dec 2023	2.05M	-22.13M	-1076.41%
Mar 2024	0	-19.70M

Aura Biosciences, Inc. (NASDAQ:AURA): Earnings per share (EPS)
2024-05-09	-0.51	-0.4

Aura Biosciences, Inc. (NASDAQ:AURA): Debt to assets
Jun 2023	192739000	26.30M	13.65%
Sep 2023	179766000	28.04M	15.6%
Dec 2023	255075000	29.22M	11.46%
Mar 2024	235025000	26.24M	11.17%

Aura Biosciences, Inc. (NASDAQ:AURA): Cash Flow
Jun 2023	-14.64M	21.40M	2.47M
Sep 2023	-15.40M	21.62M	1.62M
Dec 2023	-17.38M	-90.12M	92.98M
Mar 2024	-24.45M	9.39M	253K

Aura Biosciences alternative data

Aura Biosciences, Inc. (NASDAQ:AURA): Employee count
Aug 2023	70
Sep 2023	70
Oct 2023	70
Nov 2023	70
Dec 2023	70
Jan 2024	70
Feb 2024	70
Mar 2024	88
Apr 2024	88
May 2024	88
Jun 2024	88
Jul 2024	88

Aura Biosciences
Hedge Funds Holdings Q1 2023

23.21% -58.11%

of AURA is owned by hedge funds

32 -17

hedge funds hold AURA stock

6.94M -16.85M

shares is hold by hedge funds

AURA hedge funds holdings changes

Aura Biosciences
Insider Trading

Aura Biosciences, Inc. (NASDAQ:AURA): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	0	22462
Oct 2024	0	67259
Nov 2024	0	11822

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	18 Nov 2024	HOPKINS JANET JILL officer: Chief Medical Officer officer: Chief Medical Officer	Common Stock	11,822	$9.36	$110,666
Sale	29 Oct 2024	DE LOS PINOS ELISABET director, officer: See Remarks director, officer: See Remarks	Common Stock	9,200	$10.74	$98,790
Sale	29 Oct 2024	ELAZZOUZI AMY officer: Vice President, Finance officer: Vice President, Finance	Common Stock	553	$10.74	$5,939
Option	18 Oct 2024	FEDER JULIE B officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	5,000	$5.48	$27,400
Option	18 Oct 2024	FEDER JULIE B officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	2,631	$4.25	$11,182
Option	18 Oct 2024	FEDER JULIE B officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	17,500	$2.74	$47,950
Sale	18 Oct 2024	FEDER JULIE B officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	25,131	$12.03	$302,351
Option	18 Oct 2024	FEDER JULIE B officer: Chief Financial Officer officer: Chief Financial Officer	Stock Option (Right to Buy)	5,000	$5.48	$27,400
Option	18 Oct 2024	FEDER JULIE B officer: Chief Financial Officer officer: Chief Financial Officer	Stock Option (Right to Buy)	17,500	$2.74	$47,950
Option	18 Oct 2024	FEDER JULIE B officer: Chief Financial Officer officer: Chief Financial Officer	Stock Option (Right to Buy)	2,631	$4.25	$11,182

AURA insider trading transactions

Aura Biosciences
Latest News

Monday, 2 December 2024
04:31	Muscle Invasive Bladder Cancer Drug Pipeline Market Research 2024 Featuring Aura Biosciences, Janssen Research & Development, Asieris Pharmaceuticals, and RemeGen	globenewswire.com
Monday, 21 October 2024
15:12	Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value	seekingalpha.com
Friday, 18 October 2024
09:16	Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease	benzinga.com
Thursday, 17 October 2024
16:05	Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial	globenewswire.com
Thursday, 10 October 2024
11:12	3 Small-Cap Stocks Ready to Deliver Significant Growth	marketbeat.com
Friday, 20 September 2024
15:30	Sept. 13-20 Undercovered Stock Picks: Aura Biosciences, APA Corporation, iTeos, CuriosityStream +	seekingalpha.com
Tuesday, 17 September 2024
12:31	Aura Biosciences: Highly Derisked Late-Stage Eye Cancer Company	seekingalpha.com
Friday, 13 September 2024
10:31	Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study	zacks.com
Thursday, 12 September 2024
11:40	Aura Biosciences Touts Promising Data From Eye Cancer Candidate	benzinga.com
06:30	Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma	globenewswire.com
Tuesday, 3 September 2024
16:05	Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024	globenewswire.com
Wednesday, 28 August 2024
16:05	Aura Biosciences to Participate in Upcoming Investor Conferences	globenewswire.com
Monday, 26 August 2024
16:05	Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting	globenewswire.com
Thursday, 8 August 2024
07:00	Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights	globenewswire.com
Thursday, 6 June 2024
10:56	Wall Street Analysts See a 162.63% Upside in Aura Biosciences (AURA): Can the Stock Really Move This High?	zacks.com
Thursday, 30 May 2024
16:05	Aura Biosciences to Participate in the Jefferies Global Healthcare Conference	globenewswire.com
Thursday, 23 May 2024
08:00	Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024	globenewswire.com
Thursday, 9 May 2024
07:00	Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights	globenewswire.com
Wednesday, 8 May 2024
07:00	Aura Biosciences to Participate in Upcoming Investor Conferences	globenewswire.com
Wednesday, 27 March 2024
07:00	Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	businesswire.com
Monday, 26 February 2024
07:00	Aura Biosciences to Participate in Upcoming Investor Conferences	businesswire.com
Monday, 11 December 2023
11:17	Wall Street Analysts Think Aura Biosciences, Inc. (AURA) Could Surge 174.29%: Read This Before Placing a Bet	zacks.com
Thursday, 7 December 2023
08:00	Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma	businesswire.com
Thursday, 23 November 2023
11:16	Wall Street Analysts Believe Aura Biosciences, Inc. (AURA) Could Rally 200.75%: Here's is How to Trade	zacks.com
Wednesday, 15 November 2023
08:23	Aura Biosciences: Mid-2024 Data Could Bring Expansion Opportunity	seekingalpha.com
Wednesday, 8 November 2023
07:00	Aura Biosciences to Participate in Upcoming Investor Conferences	businesswire.com
Monday, 6 November 2023
22:02	Aura Biosciences Announces Pricing of Public Offering of Common Stock	businesswire.com
16:08	Aura Biosciences Announces Proposed Public Offering of Common Stock	businesswire.com
15:00	Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma	businesswire.com
Tuesday, 31 October 2023
16:05	Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023	Business Wire

Ideas & Opinions

Seeking Alpha 15 Nov 2023

Aura Biosciences: Mid-2024 Data Could Bring Expansion Opportunity
Seeking Alpha 27 May 2023

Aura Biosciences: Excellent Execution In The Large Ocular Cancer Market

Frequently Asked Questions (FAQ)

What's the price of Aura Biosciences stock today?

One share of Aura Biosciences stock can currently be purchased for approximately $6.4.
When is Aura Biosciences's next earnings date?

Unfortunately, Aura Biosciences's (AURA) next earnings date is currently unknown.
Does Aura Biosciences pay dividends?

No, Aura Biosciences does not pay dividends.
How much money does Aura Biosciences make?

Aura Biosciences has a market capitalization of 404.85M. Aura Biosciences made a loss 76.41M US dollars in net income (profit) last year or -$0.4 on an earnings per share basis.
What is Aura Biosciences's stock symbol?

Aura Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "AURA".
What is Aura Biosciences's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Aura Biosciences?

Shares of Aura Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does Aura Biosciences have?

As Jul 2024, Aura Biosciences employs 88 workers.
When Aura Biosciences went public?

Aura Biosciences, Inc. is publicly traded company for more then 3 years since IPO on 29 Oct 2021.
What is Aura Biosciences's official website?

The official website for Aura Biosciences is aurabiosciences.com.
Where are Aura Biosciences's headquarters?

Aura Biosciences is headquartered at 85 Bolton Street, Cambridge, MA.
How can i contact Aura Biosciences?

Aura Biosciences's mailing address is 85 Bolton Street, Cambridge, MA and company can be reached via phone at +61 75008864.
What is Aura Biosciences stock forecast & price target?

Based on 3 Wall Street analysts` predicted price targets for Aura Biosciences in the last 12 months, the avarage price target is $23. The average price target represents a 259.37% change from the last price of $6.4.

Aura Biosciences, Inc.

aurabiosciences.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

+61 75008864

85 Bolton Street
Cambridge, MA 02140

CIK: 0001501796
ISIN: US05153U1079
CUSIP: 05153U107